Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 22.7% in March

Jyong Biotech Ltd. (NASDAQ:MENS) was the recipient of a large decrease in short interest during the month of March. As of March 13th, there was short interest totaling 288,865 shares, a decrease of 22.7% from the February 26th total of 373,692 shares. Based on an average daily volume of 210,084 shares, the short-interest ratio is currently 1.4 days. Approximately 0.4% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jyong Biotech in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Jyong Biotech presently has a consensus rating of “Sell”.

Institutional Trading of Jyong Biotech

Hedge funds and other institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. bought a new position in Jyong Biotech during the fourth quarter valued at about $49,000. Man Group plc acquired a new stake in Jyong Biotech in the 4th quarter valued at about $56,000. BNP Paribas Financial Markets bought a new position in shares of Jyong Biotech during the 3rd quarter valued at about $67,000. Millennium Management LLC grew its stake in shares of Jyong Biotech by 209.4% in the 4th quarter. Millennium Management LLC now owns 40,258 shares of the company’s stock worth $159,000 after purchasing an additional 27,245 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Jyong Biotech by 19.6% in the 4th quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after purchasing an additional 10,538 shares in the last quarter.

Jyong Biotech Stock Up 13.2%

Jyong Biotech stock traded up $0.25 during trading hours on Tuesday, hitting $2.15. 222,011 shares of the company traded hands, compared to its average volume of 345,448. Jyong Biotech has a 1-year low of $1.43 and a 1-year high of $67.00. The firm’s 50-day simple moving average is $2.18 and its two-hundred day simple moving average is $22.36.

Jyong Biotech (NASDAQ:MENS) last posted its quarterly earnings data on Friday, January 9th. The company reported ($0.01) earnings per share (EPS) for the quarter.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.